Clinical case of giant extramedullar plasmacytoma in a patient with multiple myeloma
https://doi.org/10.17650/1818-8346-2023-18-4-58-63
Abstract
One possible manifestation of multiple myeloma may be extramedullary plasmacytoma, manifested by infiltration of plasma cells outside the bone marrow. In the debut of the disease, bone plasmacytomas are most often diagnosed, in contrast to extramedullary ones, which are rare. According to the literature, the presence of extramedullary plasmacytoma is an unfavorable factor characterized by an aggressive disease course, the absence of an antitumor response to standard therapy, and low overall survival rates. Therefore, the pathogenesis, clinic, diagnosis and treatment of this variant of the disease require additional study. This article presents a clinical case of an aggressive course of extensive extramedullary plasmacytoma in a patient with multiple myeloma with an assessment of various combination therapy regimens efficacy.
About the Authors
G. Sh. SafuanovaRussian Federation
Guzyal Sh. Safuanova
3 Lenina St., Ufa 450008
Yu. R. Mansurova
Russian Federation
3 Lenina St., Ufa 450008
A. A. Latypova
Russian Federation
132 Dostoevskogo St., Ufa 450005
А. U. Bagautdinova
Russian Federation
132 Dostoevskogo St., Ufa 450005
T. Yu. Rozhenkova
Russian Federation
132 Dostoevskogo St., Ufa 450005
Ch. Kh. Valiakhmetova
Russian Federation
132 Dostoevskogo St., Ufa 450005
References
1. Clinical recommendations “Multiple myeloma”, 2020.
2. Firsova M.V., Risinskaya N.V., Solovev M.V. et al. Multiple myeloma with extramedullary plasmacytoma: pathogenesis and clinical case. Onkogematologiya = Oncohematology 2022;17(4):67–80. (In Russ.). DOI: 10.17650/1818¬8346-2022¬17¬4¬67¬80
3. Thais Rodrigues da Cunha Fischer, Higashi F., de Queiroz Crusoe E., de Moraes Hungria V.T. Bilateral breast plasmacytoma: a clinical case report. Rev Bras Hematol Hemoter 2016;38(2): 166–9. DOI: 10.1016/j.bjhh.2016.03.003
4. Rosiñol L., Beksac M., Zamagni E. et al. Expert review on soft tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol 2021;194(3):496–507. DOI: 10.1111/bjh.17338
5. Parrondo R.D., Roy V., Sher T. et al. Use of KRD-PACE as salvage therapy in aggressive, relapsed/bortezomib-refractory extramedullary multiple myeloma: a report of two cases and literature review. Case Rep Hematol 2020;2020:4360926. DOI: 10.1155/2020/4360926
6. Mangiacavalli S., Pompa A., Ferretti V. et al. The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann Hematol 2017;96(1):73–80. DOI:10.1007/s00277-016-2847-z
7. Fokina E.S., Lagunova O.R., Dokshina I.A. et al. Experience in the treatment of multiple myeloma with an extramedullary component using platinum-containing PACE regimens. All-Russian scientific and practical conference with international participation “Topical issues of hematology and transfusiology” dedicated to the 90th anniversary of the Russian Scientific Research Institute of Hematology and Transfusiology. Vestnik gematologii = Bulletin of Hematology 2022;91. (In Russ.).
8. Nakastoev I.M., Novikova A.A., Grachev A.E. et al. Effectiveness of VRD-PACE chemotherapy regimens in patients with multiple myeloma with resistance to first-line therapy. Gematologiya i transfuziologiya = Hematology and Transfusiology 2020;65(S1):187. (In Russ.).
9. https://meduniver.com/Medical/gematologia/xromosomnie_anomalii_pri_ostrom_limfoblastnom_leikoze.htmlMedUniver.
Review
For citations:
Safuanova G.Sh., Mansurova Yu.R., Latypova A.A., Bagautdinova А.U., Rozhenkova T.Yu., Valiakhmetova Ch.Kh. Clinical case of giant extramedullar plasmacytoma in a patient with multiple myeloma. Oncohematology. 2023;18(4):58-63. (In Russ.) https://doi.org/10.17650/1818-8346-2023-18-4-58-63